We previously studied Oxy210, an orally bioavailable, oxysterol-based, anti-fibrotic and anti-inflammatory drug candidate for MASH, using humanized hyperlipidemic APOE*3-Leiden.CETP mice that develop MASH symptoms when fed a high fat, high cholesterol “Western” diet (WD) over 16 weeks [14]. Here, APOE is linked to metabolic dysfunction-associated steatohepatitis.